Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Asymptomatic Perioperative Myocardial Injury Affects Vascular Outcomes
A new study reports that 75 percent of cardiac damage after vascular surgery is asymptomatic or patients" symptoms are concealed by postoperative complaints such as nausea and incision pain. This damage is associated with an increased risk for mortality. Researchers have found that screening for cardiac damage following surgery helps identify high-risk patients who might benefit from more aggressive medical therapy and follow-up after discharge. These findings are from a study presented today at the 63rd Annual Meeting of the Society for Vascular Surgery®.
generic viagra online
Senate Finance Committee Won't Vote On Reform Bill Before Recess
Just one day after it appeared negotiators were on the cusp of a deal, Senate Finance Committee Chairman Sen. Max Baucus said Thursday that his committee will not vote on a health reform bill before the August recess, Politico reports. "Baucus"s announcement came after a day in which Republican negotiators on the committee made clear they were not comfortable with the Democratic timetable - pushed by President Barack Obama and other Democratic leaders." Drugshop to buy zoloft online and other pills.
News of the day
Access Pharmaceuticals Announces Publication Of Thiarabine Combination Data
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced that new Thiarabine preclinical efficacy data will shortly be published demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. In one colorectal cancer model, 66% of mice were cured of their tumors. The publication which will appear in the journal "Cancer Chemotherapy and Pharmacology," was based on work conducted by Access" collaborators at the Southern Research Institute. The paper is entitled "Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine" (thiarabine).
Oncology

Hemophilia A Mice Benefit From Gene Therapy

Hemophilia A is an inherited bleeding disease caused by a lack of the blood clotting protein Factor VIII. It had been hoped that gene therapy would provide a breakthrough in treatment, but the most common gene therapy approach has had little clinical success. However, a team of researchers, at the University of Minnesota Medical School, Minneapolis, has now developed a new approach to target genes specifically to mouse liver sinusoidal endothelial cells (the cells that are the main of Factor VIII) and used it to provide long-term expression of Factor VIII in hemophilia A mice, markedly reducing their disease. They hope that their data might prove to be a step toward successful human clinical trials in individuals with hemophilia A. The team, led by Betsy Kren and Clifford Steer, coated nanoparticles with hyaluron so that they targeted liver sinusoidal endothelial cells. To test the efficacy of gene delivery, the hyaluron-coated nanoparticles were engineered to contain a therapeutic gene (Factor VIII) together with a genetic element known as Sleeping Beauty, which helps the therapeutic gene insert into the genome of the targeted cells (i.e, the liver sinusoidal endothelial cells). Even 50 weeks after hemophilia A mice were injected with these nanoparticles, levels of Factor VIII in the blood were the same as in the blood of normal mice and bleeding times were also similar to those of normal mice. The authors hope that this combination of technologies, the cell-specific nanocapsule delivery system and the Sleeping Beauty genetic element, will prove to be a viable gene therapy. TITLE: Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice http://https://www.the-jci.org/article.php?id=34332 Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009